Hemorrhagic corpus luteum: Clinical management update.
Mykhailo V MedvedievAntonio MalvasiSarah GustapaneAndrea TinelliPublished in: Turkish journal of obstetrics and gynecology (2020)
Hemorrhagic corpus luteum (HCL) is an ovarian cyst formed after ovulation and caused by spontaneous bleeding into a corpus luteum (CL) cyst. When HCL rupture happens, a hemoperitoneum results. Clinical symptoms are mainly due to peritoneal irritation by the blood effusion. The differential diagnosis is extensive and standard management is not defined. The authors elaborated a comparison of the differential diagnosis and therapeutic modalities from the laparoscopic approach to nonsurgical, medical options because hemorrhage from HCL is often self-limiting. The authors reviewed all data implicated with the development of HCL, trying to give homogeneity to literature data. The authors analyzed extensive literature data and subdivided the medical approach into many topics. The wait-and-see attitude avoids unnecessary laparoscopic surgery using supportive therapies (antifibrinolytic, analgesics, liquid infusion, transfusions and antibiotic prophylaxis). Surgical therapy: operative management should be laparoscopic, with surgical options such as luteumectomy, ovarian wedge-shaped excision or oophorectomy. Prevention: the possibility to preserve fertility is essential, mainly in patients with bleeding disorders or undergoing anticoagulant therapy; therefore, they need estro-progestinics or GnRH analogues to prevent ovulation and avoid further episodes of HCL. This review will aid physicians in making an early diagnosis of HCL, to avoid unnecessary surgery, and use the most effective treatment.
Keyphrases
- electronic health record
- laparoscopic surgery
- atrial fibrillation
- systematic review
- healthcare
- big data
- robot assisted
- polycystic ovary syndrome
- minimally invasive
- primary care
- low dose
- replacement therapy
- stem cells
- venous thromboembolism
- machine learning
- depressive symptoms
- ionic liquid
- coronary artery bypass
- coronary artery disease
- artificial intelligence
- combination therapy